癌症杂志
Chinese Journal of Cancer 암증（영문판）
- 论文标题 期刊级别 审稿状态
-
伊马替尼、5-溴汉防己甲素逆转K562/A02细胞多药耐药的研究
Background and Objective: Research has shown that 5-bromotetrandrine (BrTet) can effectively reverse multidrug resistance (MDR). Imatinib plays an important role in cell proliferation. This study explored the efficacy of the combination of imatinib and BrTet on reversing MDR of tumor cells and its mechanism. Methods: Cytoxicity was assessed by MTT assay. Apoptosis of K562/A02 cells was analyzed by flow cytometry. The expressions of mdr1 mRNA and P-glycoprotein (P-gp) were detected using reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis. Results: After 48 h of treatment with 0.0625 umol/L imatinib, 0.5 umol/L BrTet, or both, the 50% inhibition concentration (IC50) of daunorubicin (DNR) for the K562/A02 cells were 5.69 mg/L, 5.41 mg/L, and 2.19 mg/L, respectively. The gray-scale values of mdr1 mRNA expression in the K562/A02 cells were 0.65 ± 0.02, 0.64 ± 0.01, and 0.25± 0.03, respectively. The expression levels of P-gp were 0.74 ± 0.02, 0.52 ± 0.02, and 0.29 ± 0.02, respectively. All decreased significantly in the K562/A02 cells treated with both imatinib and BrTet compared to cells treated with imatinib and BrTet alone (P < 0.05). The apoptosis rates of the K562/A02 cells increased without a significant difference after treatment with DNR, imatinib, or BrTet (P > 0.05), while increased significantly after treatment with DNR combined with imatinib, BrTet, or both (P < 0.05). Conclusions: The MDR of K562/A02 cells may be partially reversed by imatinib or BrTet, and the mechanism may be related to the downregulation of mdr1 mRNA and P-gp expression and the upregulation of the rate of apoptosis in K562/A02 cells. Imatinib combined with BrTet showed a synergistic effect on K562/A02 cells.
-
雄激素受体在三阴乳腺癌的表达及临床意义
Background and Objective: Androgen receptor (AR) is involved in the pathogenesis of breast cancer, but its role is not clearly defined. This study was to explore the expression of AR and its relationship with clinicopathologic parameters in triple negative breast cancer (negative estrogen receptor, negative progesterone receptor, and negative Her-2). Methods: Immunohistochemical assays were performed to determine the expression of AR in 137 cases of triple negative breast cancer and 132 cases of non-triple negative breast cancer. The relationships between AR expression and clinicopathologic data and prognosis were analyzed. Results: The positive rate of AR was significantly lower in triple negative breast cancer than in non-triple negative breast (27.7% vs. 83.3%,χ2 = 83.963, P < 0.001). AR expression was correlated with menorrheal status (χ2 = 6.803, P = 0.009), tumor grade (χ2 = 5.173, P = 0.023), node status (χ2 = 7.787, P = 0.005), 5-year disease-free survival (χ2 = 5.012, P = 0.025) and 5-year overall survival (χ2 = 5.552, P = 0.018) in triple negative breast cancer, but was not correlated with clinicopathologic parameters and survival in non-triple negative breast cancer. The 5-year overall survival rate was 78.8% in triple negative breast cancer and 83.3% in non-triple negative breast cancer. Conclusions: The expression of AR is related to biological behaviors of triple negative breast cancer, and plays a role in endocrinotherapy and prognostic prediction.
-
CIK细胞回输降低肝癌微创介入术后复发中AFP定量检测的临床意义
Background and Objective: In patients with hepatocellular carcinoma (HCC) receiving potentially curative minimally invasive therapy, autologous cytokine-induced killer (CIK) cells were used to reduce recurrence. In this study we observed the changes in serum alpha-fetoprotein (AFP) after the treatment with CIK cells to explore if AFP could serve as a marker for predicting immunotherapeutic clinical outcome. Methods: A total of 122 patients with HCC and elevated AFP (> 25 ng/mL) 收稿日期: a curative treatment of transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) at the Sun Yat-sen University Cancer Center. Of these patients, 83 patients without residual tumor or extrahepatic metastasis and with AFP level less than 1.5 times the normal range (AFP < 37.5 ng/mL) were randomly assigned to the study group (n = 42) and the control group (n = 41). In the study group, CIK cells were transfused intravenously or via common hepatic arteries every week for at least 4 times, and the T-lymphocyte subset data before and after CIK cell infusions was examined by flow cytometry. All the two groups of patients were screened by tomography every 2 months to observe tumor recurrence. Serum AFP was collected at baseline and at different time points after treatment in parallel with radiologic response and clinical outcome. Results: Two patients in the control group were lost to follow-up after treatment. After CIK cell infusions, the downtrend of the AFP level was observed in the study group and not in the control group. There was a significant difference in the level of AFP between different time points after CIK infusions in both groups. The 1-year recurrence rate was 7.14 % for the study group and 23.1% for the control group (P = 0.044). In subgroup analysis, for patients with a slightly high level of AFP (25 ng/mL < AFP < 37.5 ng/mL) after curative TACE plus RFA treatment, the 1-year recurrence rate was 28.57% for the study group and 80% for the control group. The time to recurrence in the study group was also longer than that in the control group (mean 10.2 months vs. 6.8 months). After CIK cell infusions, the percent of CD3+CD4+ T cells and CD4+ /CD8+ T cells increased from 28.1 ± 5.9% and 0.9 ± 0.3% to 32.7 ± 3.6% and 1.2 ±0.2% (P < 0.001 and = 0.004, respectively), while the percent of CD3+CD8+ T cells decreased from 32.9 ±8.4% to 28.8 ± 2.2% (P = 0.046). Also the percentage of patients with hepatitis B virus (HBV)-DNA content less than 1 × 103 copies/mL was 73.5% in the study group and 9.1% in the control group. Conclusions: CIK cells transfusion may reduce the level of serum AFP and anti-HBV and decrease the 1-year recurrence rate of patients with HCC after curative TACE plus RFA. Serum AFP decrease after CIK cell treatment may serve as a useful marker for predicting immunotherapy clinical outcome in patients with HCC undergone curative minimally invasive therapy.
-
microRNA-29s对胃癌细胞增殖和侵袭的作用
Background and Objective: MicroRNAs have emerged as post-transcriptional regulators that are critically involved in the biologic behavior of cells. This study was designed to investigate the effect of members of the microRNA-29 family on the expression of cell division cycle 42 (Cdc42) and their roles on proliferation, migration, and invasion of gastric cancer cells. Methods: We detected microRNA-29s and Cdc42 expression in gastric cancer cells by real-time polymerase chain reaction (PCR) and Western blot analysis. Negative controlled RNA (ncontrol), microRNA-29 family members (microRNA-29a, -29b, and -29c), and Cdc42-specific small interfering RNA (si-Cdc42) were chemically synthesized and transfected into SGC7901 and BGC823 gastric cancer cells, which have a relatively low expression of microRNA-29s and a relatively high expression of Cdc42. The expression of Cdc42 and the phosphorylation of its downstream molecular PAK1 expressions were determined by Western bott analysis. Cell Counting Kit-8 was used to measure cell proliferation, and wound-healing and invasion assays were used to examine the abilities of migration and invasion. Results: Similar to si-Cdc42, the ectopic expression of microRNA-29 family members significantly reduced the expression of Cdc42 and its downstream molecular PAK1 phosphorylation levels. Consistently, ectopic expression of microRNA-29s inhibited proliferation and migration in gastric cancer cells. Invasive cell counts of the SGC7901, ncontrol/SGC7901, si-Cdc42/ SGC7901, microRNA-29a/SGC7901, microRNA-29b/SGC7901, and microRNA-29c/SGC7901 cell groups were 84.0 ±4.2, 71.7± 4.6, 16.3 ± 3.2, 15.7 ± 3.8, 16.3 ± 3.0, and 16.7± 3.1, respectively. The invasive cell counts of the BGC823, ncontrol/BGC823, si-Cdc42/BGC823, microRNA-29a/BGC823, microRNA-29b/BGC823, and microRNA-29c/BGC823 cell groups were 199.0 ± 10.5, 146.3 ±9.7, 72.7 ± 8.2, 86.7 ± 8.5, 86.0 ± 8.5, and 73.3 ± 8.3, respectively (P < 0.05). Conclusions: Members of the microRNA-29 family can obviously inhibit cell proliferation, migration, and invasion of gastric cancer cells by targeting Cdc42.
-
人原发性胃恶性淋巴瘤裸鼠原位移植肝转移模型的建立
Background and Objective: In recent years, incidence and mortality of lymphoma are markedly increasing worldwide. However, the pathogenesis and mechanism of invasion and metastasis for lymphoma are not yet fully clarified. It is mainly due to the lack of ideal animal models, which can precisely simulate the invasion and metastasis of lymphoma in the human body. So, it is very necessary to establish a highly metastatic nude mouse model of human lymphoma. This study developed a liver-metastatic model of primary gastric lymphoma in nude mice by using orthotopic surgical implantation of histologically intact patient specimens into the corresponding organs of the recipient small animals. Methods: A histologically intact fragment of liver metastasis derived from a surgical specimen of a patient with primary gastric lymphoma was implanted into the submucosa of the stomach in nude mice. Tumorigenicity, invasion, metastasis, morphologic characteristics (via light microscopy, electron microscopy, and immunohistochemistry), karyotype analysis, and DNA content of the orthotopically transplanted tumors were studied. Results: An orthotopic liver metastatic model of human primary gastric lymphoma in nude mice (termed HGBL-0304) was successfully established. The histopathology of the transplanted tumors showed primary gastric diffuse large B-cell lymphoma. CD19, CD20, CD22, and CD79a were positive, but CD3 and CD7 were negative. The serum level of lactate dehydrogenase (LDH) was elevated [(1010.56± 200.85) U/L]. The number of chromosomes ranged from 75 to 89. The DNA index (Dl) was 1.45 ± 0.25 (that is, heteroploid). So far, the HGBL-0304 model has been passed on for 45 generations of nude mice. A total of 263 nude mice were used for the transplantation. Both the growth and resuscitation rates of liquid nitrogen cryopreservation of the transplanted tumors were 100%. The transplanted tumors autonomically invasively grew and damaged a whole layer in the stomach of nude mice. The metastasis rates of liver, spleen, lymph node, and peritoneal seeding were 100%, 94.3%, 62.6%, and 43.5%, respectively. Conclusions: The study successfully establishes an orthotopic liver metastatic model of human primary gastric lymphoma in nude mice. The HGBL-0304 model can completely simulate the natural clinical process of primary gastric lymphoma and provides an ideal animal model for the research on the biology of metastasis and antimetastatic experimental therapies of primary gastric lymphoma.
-
SA-IL-2锚定修饰治疗表浅膀胱癌的实验研究
Background and Objective: Intravesical administration of Bacillus Calmette-Guerin (BCG) after transurethral resection is by far the most effective local therapy for superficial bladder cancer, the fifth most common cancer in the world. However, approximately one-third of patients fail to respond and most patients eventually relapse. In addition, there are pronounced side effects of BCG therapy, such as BCG sepsis and a high frequency of BCG-induced cystitis. This study established a novel immunotherapy through immobilization of streptavidin-tagged human IL-2 (SA-hlL-2) on the biotinylated mucosal surface of bladder wall. Methods: A mouse orthotopic model of MB49 bladder cancer was established by perfusing MB49 cells into mouse bladders. The SA-hlL-2 fusion protein was immobilized on the biotinylated mucosal surface of the bladder wall. Treatment began on day 1 after MB49 implantation, once every 3 days for 6 times. Immunohistochemical assay was performed to assess the persistence of SA-hlL-2 immobilized on the biotinylated mucosal surface of the bladder wall. The mice were monitored for tumor growth and survival. On day 60 after MB49 implantation, the SA-hlL-2-cured mice, which were found to have no hematuria or palpable tumors, were challenged with wild-type MB49 cells implanted into the pretreated bladder and monitored for survival. Results: SA-hlL-2 could be immobilized efficiently and durably on the bladder mucosal surface as long as 7 days. On day 60 after MB49 implantation, 9 out of 20 SA-hlL-2-treated mice survived, but all mice in PBS control group died. More importantly, 5 out of 9 tumor-free mice in the SA-hlL-2 group were protected against a second intravesical wild-type MB49 tumor challenge. Conclusions: SA-hlL-2 fusion protein could significantly inhibit tumor growth and extend the survival time in the orthotopic model of MB49 bladder cancer.
-
氯离子通道蝎毒素在肿瘤影像诊断及靶向治疗中的应用研究进展
Precisely locating tumors always proves to be difficult. To find a molecule that can specifically bind to tumor cells is the key. Recently, chlorotoxin (CTX) has been proved to be able to bind to many kinds of tumor cells. The CTX receptor on the cell surface has been demonstrated to be matrix metalloproteinase-2 (MMP-2). Many researchers have combined CTX with other molecules, including 131I, Cy5.5, iron oxide nanoparticles coated by polyethylene glycol (NP-PEG), and so on, and thus synthesized various types of probes that can be detected by y-camera, single photon emission computed tomography (SPECT) or magnetic resonance imaging (MRI). With these methods, the binding degree of CTX could be assessed. These studies demonstrated that CTX has a highly specific binding ability, high stability, and security. CTX could also inhibit or kill the tumor cells. A nonviral nanovector has been developed for gene therapy. As a result, it gradually develops into a new method of diagnosis and targeted therapy of tumors. This article reviews the current progress on CTX including the origin, chemical construction, the mechanism of binding with tumor cells, and the application to tumor imaging diagnosis and therapy.
-
斑马鱼神经胶质瘤模型研究进展
Glioma derived from the neural ectoderm is the most common brain tumor and is of great damage to human health among all lethal tumors. Scientists have been trying their best to find new methods and develop new drugs to treat glioma in recent years. The animal glioma model is of great importance to the research. Researchers have developed many animal glioma models, like the rat and mouse model. Now we are trying to develop a new zebrafish glioma model, which has much more advantages and fewer disadvantages than the traditional models in regard to gene mutation, chemical induction, and xenografts. Establishing a glioma model in zebrafish is feasible and would be of great use to patients with this common brain tumor.
-
伴有淀粉样物质沉积皮肤缘区B细胞淋巴瘤临床病理特点
Background and Objective: Amyloid deposition is rare. If there was a great amount of amyloid depositions in the skin tissue, it would be considered to be amyloid deposition disease at first, and then primary cutaneous marginal zone B-cell lymphoma (PCMZL). This study was to analyze the diagnosis and differential diagnosis of two cases of PCMZL with amyloid deposition. Methods: Clinicopathologic characteristics and follow-up of two cases of PCMZL were analyzed. Immunohistochemical staining was performed by EnVision method using antibodies LCA, CD19, CD20, CD79a, CD3, CD7, MUM1, k, A, Ki-67. IgH and TCRy gene rearrangement was detected by polymerase chain reactive (PCR). Results: Case 1, a 71-year-old Chinese male, had a subcutaneous mass on the right elbow that was initially diagnosed with "amyloidosis" in 2004. Three years after the initial diagnosis, he developed recurrences on the right para-auxillary that was still diagnosed with "probably amyloidosis". Four years after the first diagnosis, the patient presented a lesion on the right para-auxiliary with a diameter of 2 cm and a lesion on the temporal-parietal dural with a size of 6.0 cm × 3.0 cm × 3.0 cm. Case 2, a 68-year-old Chinese male, had a subcutaneous mass next to back of the left ear with a size of 9.0 cm × 5.0 cm, and he underwent a operation one year previously because of subcutaneous mass in the same site. Microscopically, the tumors of both cases were located in dermis and subcutaneous, tumor cells were medium size with a nodular or diffuse distribution, and some of tumor cells were plasmacytoid/plasma cells. Morphologically, the temporal-parietal dural lesion was similar to subcutaneous lesion and infiltrated into cranial (case 1). Juxtaposed the tumor cells of two cases, there were the large amyloid deposits of amorphous hyaline material and concentrically laminated hyaline spherules in case 1, while cord-like amyloid deposits in case 2. Reactive lymphoid follicles with germinal centers and foreign body giant cells in the stroma were found surrounding the amyloid deposits. Congo red staining showed positive of amyloid deposition in tumor tissues of both cases. Immunohistochemical staining revealed that LCA, CD19, CD20, CD79a and MUM1 expressions were positive in tumor cells, and Ki-67 expression was about 8%-10%. IgL restricted expression as κ positive while A negative was found in both cases. PCR results showed monoclone gene rearrangement of IgH gene in both cases. Conclusions: Our findings suggest that amyloid deposition rarely present in both primary and metastatic tumors in PCMZL, and its diagnosis should be considered to avoid misdiagnosis. The patients with PCMZL should undergo regular examinations and chemotherapy as well as a long-term follow-up since it is apt to recur or relapse.
-
Synovial sarcoma:a rare presentation of parapharyngeal mass
Synovial sarcoma is a rare soft tissue sarcoma of the head and neck region involving the parapharyngeal space. The diagnosis of synovial sarcoma can be very challenging to the pathologists. We present a rare case of parapharyngeal synovial sarcoma in a young female patient who had a two-month history of left cervical intumescent mass at level II. The fine needle aspiration cytology of the mass was proved inconclusive. Transcervical excision of the mass was performed and the first case of parapharyngeal sarcoma was identified in our center by fluorescence in situ hybridization (FISH) technique. Repeat imaging revealed residual tumor. The patient successfully underwent a second excision of the residual tumor and 收稿日期: adjuvant radiotherapy.
-
二维半导体探测器阵列的方向性响应和在调强放射治疗合成剂量验证中的应用研究
Background and Objective: The planning dose distribution of intensity-modulated radiation therapy (IMRT) has to be verified before clinical implementation. The commonly used verification method is to measure the beam fluency at 0 degree (0°) gantry angle with a 2-dimensional (2D) detector array, but not the composite dose distribution of the real delivery in the planned gantry angles. This study was to investigate the angular dependence of a 2D diode array (2D array) and the feasibility of using it to verify the composite dose distribution of IMRT. Methods: Angular response of the central detector in the 2D array was measured for 6 MV X-ray, 10 cm × 10 cm field and 100 cm source axis distance (SAD) in different depths. With the beam incidence angle of 0°-60°, at intervals of 10°, and inherent buildup of the 2D array (2 g/cm2), the array was Irradiated and the readings of the central diode were compared with the measurement of thimble ionization chamber. Using a combined 30cm×30cm×30cm phantom which consisted of solid water slabs on top and underlying the 2D array, with the diode detectors placed at 8 g/cm2 depth, measurements were taken for beam angles of 0°-180° at intervals of 10° and compared with the calculation of treatment planning system (TPS) that pre-verified with ion chamber measuring. Results: Differences between the array detector and thimble chamber measurements were greater than 1% and 3.5% when the beam angle was larger than 30° and 60°, respectively. The measurements in the combined phantom were different from the calculation as high as 20% for 90° beam angle, 2% at 90°± 5° and less than 1% for all the other beam angles. Conclusions: The 2D diode array is capable of being used in composite dose verification of IMRT when the beam angles of 90°±5° and 270°± 5° are avoided.
| 年 | 期数 |
| 2019 | 01 |
| 2018 | 01 02 03 04 05 06 07 08 11 12 |
| 2017 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2016 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2015 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2014 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2013 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2012 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2011 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2010 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2009 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2008 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2007 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2006 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2005 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2004 | 01 02 03 04 05 06 07 08 09 10 11 12 z1 |
| 2003 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2002 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 2001 | 01 02 03 04 05 06 07 08 09 10 11 |
| 2000 | 01 02 03 04 05 06 07 08 09 10 11 12 |
| 1999 | 01 02 03 04 05 06 Z1 |
